Wa'el Hashad

Wa’el Hashad joined Longeveron in the role of CEO on March 1, 2023, bringing with him more than 35 years of experience in the pharmaceutical and biotech industries.

Prior to joining Longeveron, Mr. Hashad was the President and CEO of Avanir Pharmaceuticals where he led all aspects of the company’s commercial initiatives and the product development pipeline. Avanir was fully integrated into Otsuka on December 22, 2022. In his career before Avanir, Mr. Hashad was the Chief Commercial Officer of Seres Therapeutics, where he spearheaded both strategy and development of various therapeutic types, including several microbiome-based therapies. Mr. Avenir is an accomplished leader, who has held senior leadership positions at Amgen, Boehringer Ingelheim and Eli Lilly and Company.

He has launched several successful brands in the U.S. and worldwide markets. His therapeutic expertise includes cardiovascular, neuroscience, endocrine and inflammatory diseases. He is passionate about innovation and advancing science. Mr. Hashad holds a Bachelor of Science in Pharmacy from Cairo University and a Master of Business Administration from University of Akron in Ohio